"Rebound growth of infantile hemangiomas (IHs) may occur in up to a quarter of patients treated with oral propranolol (OP) therapy, and early discontinuation of therapy may double this risk, according to a new retrospective study. These findings a"...
SYNALAR® Solution is indicated for the relief of the inflammatory and pruritic manifestations of corticosteriod-responsive dermatoses.
DOSAGE AND ADMINISTRATION
SYNALAR® Solution is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion.
If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
SYNALAR® (fluocinolone acetonide) Topical Solution, 0.01%
60 mL Bottle with applicator
tip – NDC 43538-920-60
90 mL Bottle with applicator tip – NDC 43538-920-90
Store at room temperature 15-25°C (59-77°F); avoid freezing and excessive heat above 40°C (104°F).
To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda/gov/medwatch.
Manufactured for: Medimetriks Pharmaceuticals, Inc., 363 Route 46 West, Fairfield, NJ 07004-2402 USA. Manufactured by: IGI Laboratories, Inc., Buena, NJ 08310. Revised: 11/2012This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/10/2012
Additional Synalar Information
Synalar - User Reviews
Synalar User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.